Imugene presents new data on cancer vaccines AACR

Company News

by Rachael Jones

Biotech company Imugene (ASX:IMU) presented new data on the KEY-Vaxx and B-Vaxx cancer vaccine programs at the American Association for Cancer Research Annual Meeting this week.

Dr Tanios Bekaii-Saab from the Mayo Clinic highlighted the key finding of the KEY-Vaxx showing when combined with B-Vaxx its more effective in reducing tumour growth in a validated mouse model of colon carcinoma versus either the PD-1 KEY-Vaxx vaccine alone.

Imugene’s KEY-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours such as lung cancer by interfering with PD-1/PD-L1 binding and interaction, and produce an anti-cancer effect.

Shares in Imugene (ASX:IMU) last traded at 2 cents.